An orexin receptor antagonist, suvorexant, has been approved as a drug for the treatment of insomnia and widely used to date in Japan. The administration of suvorexant improved glucose metabolism in db/db mice, without affecting body weight, food intake, and insulin sensitivity [1] , proposing favorable effects of suvorexant on metabolic parameters in animal models. However, effects of suvorexant on metabolic parameters in humans had been remained unknown.
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Very recently, we have reported an unfavorable effect of an orexin receptor antagonist (suvorexant) on metabolic parameters and blood pressure [2] . In our study, body weight, systolic and diastolic blood pressures, hemoglobin A1c (HbA1c) and low-density lipoprotein-cholesterol (LDL-C) significantly increased at some points after the start of suvorexant. Surprisingly, suvorexant significantly reduced high-density lipoprotein-cholesterol (HDL-C) at 3, 4, 6, 8 and 9 months after its start. Because these undesirable effects are not negligible problems and more detailed analysis was desired, we analyzed them separately for diabetic patients and non-diabetic patients.
In diabetic patients (n = 45, age, 66.9 ± 13.4 (mean ± SD) years; male/female, 20/25), body weight, systolic blood pressure, HbA1c, LDL-C and triglyceride (TG) did not show any changes, however, HDL-C significantly decreased at 1 (n = 24; from 55.0 ± 14.0 to 51.5 ± 13.6 mg/dL, P = 0.036 by paired t test) and 3 (n = 16; from 50.9 ± 10.6 to 46.1 ± 10.2 mg/dL, P = 0.011) and 8 months (n = 9; from 49.0 ± 13.0 to 43.8 ± 10.1 mg/dL, P = 0.050) after the start of suvorexant. Diastolic blood pressure significantly increased (n = 7; from 64.9 ± 16.5 to 74.1 ± 12.4 mm Hg, P = 0.020) after 8 months.
In non-diabetic patients (n = 43, age, 48.8 ± 20.4 years; male/female, 14/29), body weight, systolic and diastolic blood pressures and TG did not change, however, HbA1c significantly increased at 6 (n = 6; from 5.8±0.5% to 6.1±0.5%, P = 0.022) and 9 months (n = 3; from 5.4±0.1% to 5.7±0.1%, P = 0.010) after the start of suvorexant. Serum LDL-C levels were significantly elevated at 1 (n = 12; from 114.7 ± 31.4 to 126.3 ± 35.2 mg/dL, P = 0.035) and 10 months (n = 5; from 96.0 ± 27.7 to 124.0 ± 43.6 mg/dL, P = 0.044) after the start of suvorexant. Serum HDL-C significantly decreased at 3 (n = 9; from 72.1 ± 28.0 to 66.2 ± 31.0 mg/dL, P = 0.027) and 8 months (n = 5; from 69.4 ± 23.3 to 54.2 ± 16.3 mg/dL, P = 0.033) after the start of suvorexant. However, a significant increase of serum HDL-C was observed after 10 months (n = 4; from 54.0 ± 13.8 to 60.0 ± 15.0 mg/dL, P = 0.043).
Present sub-analysis showed that suvorexant exacerbated blood pressure and lipid metabolism in diabetic patients and exacerbated glucose and lipid metabolism in non-diabetic patients. A prospective study to examine the effect of suvorexant on blood pressure, glucose and lipid metabolism is desired, and at the same time it is necessary to conduct a cohort study on the effect of suvorexant on cardiovascular events.
